IMNM has 36-month beta value of 1.91. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IMNM is 69.73M, and currently, short sellers hold a 15.12% ratio of that float. The average trading volume of IMNM on February 12, 2025 was 1.01M shares.
IMNM) stock’s latest price update
Immunome Inc (NASDAQ: IMNM) has experienced a decline in its stock price by -8.47 compared to its previous closing price of 11.22. However, the company has seen a fall of -7.31% in its stock price over the last five trading days. businesswire.com reported 2025-02-06 that BOTHELL, Wash.–(BUSINESS WIRE)–Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on February 3, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 51,000 shares of common stock to four new employees under the Company’s 2024 Indu.
IMNM’s Market Performance
IMNM’s stock has fallen by -7.31% in the past week, with a monthly drop of -3.11% and a quarterly drop of -18.10%. The volatility ratio for the week is 10.17% while the volatility levels for the last 30 days are 8.71% for Immunome Inc The simple moving average for the past 20 days is -0.64% for IMNM’s stock, with a -21.31% simple moving average for the past 200 days.
Analysts’ Opinion of IMNM
Many brokerage firms have already submitted their reports for IMNM stocks, with Stephens repeating the rating for IMNM by listing it as a “Overweight.” The predicted price for IMNM in the upcoming period, according to Stephens is $30 based on the research report published on November 08, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see IMNM reach a price target of $27. The rating they have provided for IMNM stocks is “Overweight” according to the report published on May 31st, 2024.
JP Morgan gave a rating of “Overweight” to IMNM, setting the target price at $24 in the report published on April 30th of the previous year.
IMNM Trading at -9.38% from the 50-Day Moving Average
After a stumble in the market that brought IMNM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.83% of loss for the given period.
Volatility was left at 8.71%, however, over the last 30 days, the volatility rate increased by 10.17%, as shares surge +2.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.93% lower at present.
During the last 5 trading sessions, IMNM fell by -7.31%, which changed the moving average for the period of 200-days by -28.03% in comparison to the 20-day moving average, which settled at $10.34. In addition, Immunome Inc saw -3.30% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMNM starting from SIEGALL CLAY B, who purchase 150,000 shares at the price of $7.75 back on Jan 31 ’25. After this action, SIEGALL CLAY B now owns 669,636 shares of Immunome Inc, valued at $1,162,500 using the latest closing price.
SIEGALL CLAY B, the President and CEO of Immunome Inc, purchase 66,057 shares at $9.54 during a trade that took place back on Nov 21 ’24, which means that SIEGALL CLAY B is holding 485,693 shares at $630,263 based on the most recent closing price.
Stock Fundamentals for IMNM
Current profitability levels for the company are sitting at:
- -31.34 for the present operating margin
- 0.88 for the gross margin
The net margin for Immunome Inc stands at -30.15. The total capital return value is set at -1.46. Equity return is now at value -276.36, with -174.46 for asset returns.
Based on Immunome Inc (IMNM), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -31.68. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1579.52.
Currently, EBITDA for the company is -28.27 million with net debt to EBITDA at 1.36. When we switch over and look at the enterprise to sales, we see a ratio of 70.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.17.
Conclusion
To put it simply, Immunome Inc (IMNM) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
